Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

Recruiting now

Conditions studied: HR+/HER2- Early Breast Cancer

In brief

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

Key facts

Study ID

NCT07531693

Run by

Institut fuer Frauengesundheit

People needed

200

Starts

2026-02-19

Expected to finish

2027-03-01

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Femal patients age 18 or older at time of informed consent
• Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis)
• Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
• Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025

You may not qualify if…

• Locally advanced or metastatic breast cancer
• Male patients
• Patients with contraindication(s) for abemaciclib therapy according to SmPC

Where it is running

• Department of Obstetrics and Gynaecology, Uniklinikum Erlangen — Erlangen, Bavaria, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.